Bernardo Stefanini

机构：Hammersmith Hospital, Azienda USL di Bologna, Imperial College London, University of Bologna · ORCID：0000-0003-3800-5678

发表论文 126 篇 · 总被引 939 次 · h-index 16

代表论文

• Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study (2025 · JHEP Reports · 被引 12)
• Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma (2025 · JAMA Oncology · 被引 9)
• Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab (2025 · Liver International · 被引 6)
• Pure red cell aplasia due to Parvovirus B19 infection and atezolizumab: case report and literature review (2025 · Immunotherapy · 被引 5)
• Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study (2025 · Liver Cancer · 被引 5)
• Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials (2026 · World Journal of Gastroenterology · 被引 4)